Healthcare Equipment and Supplies
Company Overview of Boston Heart Diagnostics Corporation
Boston Heart Diagnostics Corporation develops lipid tests and methodologies for cardiovascular risk assessment and disease management. The company offers integrated diagnostics, personalized reporting, and lifestyle management solutions that enable healthcare providers and patients to improve heart health and prevent disease. Its solutions include Boston Heart HDL Map, a test that quantifies the amount of apoA-I in the five most significant subpopulations, resulting in an understanding of a patient’s cardiovascular disease (CVD) risk; Boston Heart Cholesterol Balance Test, a test that directly measures the production and absorption markers for circulating plasma cholesterol; Boston Heart Sta...
175 Crossing Boulevard
Framingham, MA 01702
Founded in 2007
Key Executives for Boston Heart Diagnostics Corporation
Chief Executive Officer, President and Director
Co-Founder, Chief Medical Officer, Director and Member of Scientific Advisory Board
Co-Founder, Chief Scientific Officer and Member of Scientific Advisory Board
Senior Vice President of Operations
Compensation as of Fiscal Year 2014.
Boston Heart Diagnostics Corporation Key Developments
Boston Heart Cardiovascular Diagnostics and Services Earn Coverage Agreement from a National Health Insurer
Dec 1 14
Boston Heart announced that it has entered into a national agreement with a health insurance company that is dedicated to helping people improve their health, well-being and sense of security, to provide in-network advanced diagnostic testing. Effective January 1, 2015, this agreement will expand access of Boston Heart testing, personalized reporting, and health literacy tools to the insurer's 13 million, largely self-insured employer members throughout the United States.
Boston Heart Diagnostics Corporation Launches FDA-Cleared MPO (Myeloperoxidase) Test
Mar 6 14
Boston Heart Diagnostics Corporation announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke. The launch of MPO is an important addition to the suite of next-generation diagnostics the company already offers. More than lab results, Boston Heart gives healthcare providers the tools they need to identify risk, individualize treatment plans, and engage patients in preventing and reversing cardiovascular disease. Boston Heart offers the MPO test as an individual assay, or as part of a panel of other critical inflammation markers including hs-CRP and LpPLA. Unlike other MPO assays on the market, the Boston Heart MPO test does not require a separate sample tube, nor do office staff need to spend time aliquoting. Patients may benefit from having fewer tubes of blood drawn, and the risk of specimen rejection and redraw may be reduced, since aliquoting can be a cause of insufficient sample.
Boston Heart Diagnostics Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 03:00 PM
Jan 10 14
Boston Heart Diagnostics Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 03:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Susan Hertzberg, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 8, 2014